PRECEDE
PRECEDE is a very large international study following people whose genes or family history put them at high risk of pancreatic cancer, with yearly scans and stored blood samples, to find out how to catch the cancer early enough to cure it; it is still enrolling towards 20,000 participants.
Overview
PRECEDE (the Pancreatic Cancer Early Detection Consortium) is a prospective observational cohort registered by Arbor Research Collaborative for Health and run across more than 40 academic centres. It enrols people at high risk of pancreatic ductal adenocarcinoma, including carriers of germline pathogenic variants, members of familial pancreatic cancer kindreds, people with pancreatic cysts and cohorts with new-onset diabetes, in defined cohorts with protocol-driven surveillance imaging and longitudinal biospecimen collection. The primary outcome is the development of pancreatic ductal adenocarcinoma; the consortium's stated aim is to raise five-year survival by detecting the disease at a curable stage.
The registry lists an estimated 20,000 participants with completion in 2030 and no results. With the older CAPS programme it defines high-risk surveillance on the corpus's pancreatic cancer page.
Similar pages
not linked directly; found by shared links- TrialESPAC-4
Shares Pancreatic ductal adenocarcinoma and the tag soc-trials.
- TrialCONKO-001
Shares Pancreatic ductal adenocarcinoma and the tag soc-trials.
- TrialESPAC-5
Shares Pancreatic ductal adenocarcinoma and the tag soc-trials.
- TrialESPAC-3
Shares Pancreatic ductal adenocarcinoma and the tag soc-trials.
- TrialLAP07
Shares Pancreatic ductal adenocarcinoma and the tag soc-trials.
- Key paperEuropean evidence-based guidelines on pancreatic cystic neoplasms (2018)
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.
- Key paperRevised international consensus Fukuoka guidelines for the management of IPMN of the pancreas (2017)
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.
- Key paperInternational evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas (2024)
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.